Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

Real-World Comparison of Reference Infliximab versus the Biosimilar Infliximab-abda in Inflammatory Bowel Disease

2020 Year in Review - Biosimilars - Biosimilars

Data from a large, nationwide, observational cohort study demonstrate that switching from reference infliximab to biosimilar infliximab-abda in patients with inflammatory bowel disease was safe and efficacious compared with continuing reference infliximab.

Several biosimilars to approved biologic agents have been developed for the management of a variety of immune-mediated inflammatory disorders, such as moderate-to-severe inflammatory bowel disease (IBD), including both Crohn’s disease (CD) and ulcerative colitis (UC). A large, nationwide, prospective, observational cohort study was conducted to evaluate the efficacy and safety of biosimilars in patients with IBD who switched from reference infliximab to biosimilar infliximab-abda compared with those who continued reference infliximab; the results of this study were presented at the American College of Gastroenterology 2020 meeting.

The chart review identified eligible patients with CD or UC who had received ≥1 doses of either infliximab or infliximab-abda from 2018 to 2019 at the Cleveland Clinic. Eligible patients were randomized into 2 cohorts; the first cohort included patients authorized for a nonmedical switch from infliximab to infliximab-abda, and the second cohort included patients who continued on infliximab. Statistical analysis consisted of between-cohort comparisons using nonparametric testing for continuous variables and categorical variables (α ≤0.05).

A total of 359 patients were included in the analysis; of these, 99 patients were switched from infliximab to infliximab-abda and 101 continued infliximab therapy. In terms of baseline demographics, the mean age of the total cohort was 41.95 years, 49% were male, and 87% were white. A higher proportion of patients with CD were included than UC in both cohorts. No clinically significant differences were observed in the use of corticosteroid taper and maintenance, fecal calprotectin, infliximab concentrations, antibody levels, and hospital and emergency department admissions.

The results of the observational study demonstrated that nonmedical switch from reference infliximab to biosimilar infliximab-abda was safe and efficacious compared with continuing reference infliximab therapy in patients with IBD.

Reference
Padival R, et al. American College of Gastroenterology (ACG) 2020 Virtual Annual Scientific Meeting & Postgraduate Course. Abstract P1625.

Related Items
Rapid Biosimilar Adoption Possible in Community Oncology Practice
Charlie Dawson
TON - October 2021 Vol 14, No 5 published on October 14, 2021 in Biosimilars
Biosimilars Year in Review Introduction
2020 Year in Review - Biosimilars published on January 24, 2021 in Biosimilars
Establishing Analytical and Clinical Similarity Between HD201 and Trastuzumab
2020 Year in Review - Biosimilars published on January 24, 2021 in Biosimilars
Population-Based, Real-World Data of Neoadjuvant Chemotherapy + Pertuzumab + SB3 in HER2-Positive, Early Breast Cancer
2020 Year in Review - Biosimilars published on January 24, 2021 in Biosimilars
Cost-Savings from Conversion from Reference Pegfilgrastim with On-Body Injector Device to Biosimilar Pegfilgrastim-jmdb in DLBCL
2020 Year in Review - Biosimilars published on January 11, 2021 in Biosimilars
Pharmacokinetic and Safety Equivalence Demonstrated Between HD204, a Biosimilar of Bevacizumab, in Healthy Male Subjects
2020 Year in Review - Biosimilars published on January 11, 2021 in Biosimilars
Utilization and Adherence Among Infliximab Biosimilar Initiators in a US National Commercial Insurance Database
2020 Year in Review - Biosimilars published on January 11, 2021 in Biosimilars
US Oncologists’ Perception of the Efficacy, Safety, and Willingness to Prescribe Biosimilar Cancer Therapies
2020 Year in Review - Biosimilars published on January 11, 2021 in Biosimilars
Adherence Patterns Among Patients Using Infliximab Originator and Its Biosimilars
2020 Year in Review - Biosimilars published on January 11, 2021 in Biosimilars
Outcomes in Patients with IBS Who Initiate or Switch to the Infliximab Biosimilar Infliximab-dyyb (ONWARD Study)
2020 Year in Review - Biosimilars published on January 11, 2021 in Biosimilars
Last modified: July 22, 2021